+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

In Vitro Diagnostics Market Size, Share & Trends Analysis Report by Product, by Technology (Molecular Diagnostics, Clinical Chemistry), by Application, by End Use, and Segment Forecast, 2020 - 2027

  • ID: 4582041
  • Report
  • February 2020
  • Region: Global
  • 159 pages
  • Grand View Research
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Abbott Laboratories
  • bioMerieux
  • Cepheid
  • Danaher
  • F. Hoffmann-La Roche Ltd
  • Hologic, Inc. (Gen Probe)
  • MORE
The global in vitro diagnostics (IVD) market is expected to reach USD 85.8 billion by 2027. It is projected to exhibit a 4.4% CAGR over the forecast period. Development of simplified diagnostic tests is expected to drive the growth. For instance, Cepheid’s Xpert HCV VL Fingerstick received CE-IVD clearance in September 2018. This test identifies and measures HCV RNA levels from fingerstick blood sample.

Key players are developing new products and undertaking strategic initiatives, such as collaborations, mergers and acquisitions to gain greater market share and to expand their product portfolio. For instance, in February 2018, a product named PAXgene Blood ccfDNA tube was made available by BD for non-invasive prenatal testing and cancer diagnosis and application in the European Economic Area (EEA) and Switzerland. PAXgene Blood ccfDNA tube was developed by Qiagen-PreAnalytiX GmbH and BD in a joint venture.

Rising geriatric population and favorable government regulations to spur the approval process of medical devices are the factors expected to drive the market over the forecast period. For instance, in August 2018, approval process for IVD was eased in an amended provision in the Fourth Schedule of Medical Devices Rule by the central government of India.

Furthermore, increasing demand for early diagnosis to strategize complete treatment plans for patients by the physicians is projected to fuel the demand for user-friendly in vitro diagnostic products. For instance, in July 2017, bioMerieux for VITEK MS received the U.S. Food and Drug Administration (FDA) approval. It is a mass spectrometry system that rapidly identifies pathogens, such as Nocardia mycobacteria, and molds.

Reagents held the largest market share in 2019, owing to development of analytical laboratory automation coupled with high usage rate of reagents. For instance, in July 2018, Surmodics, Inc. launched MatrixGuard Diluent that blocks matrix or assay signal and maintains intended signals.

Increasing prevalence cancer, cardiovascular disorders, diabetes, and other diseases is expected to accelerate the demand for in vitro diagnostics in the forthcoming years. According to Cancer Research UK, in 2018, about 17 million new cancer cases were reported across the world. It has estimated that the incidence rate of the disease will witness a 62% rise from 2018 to 2040. Liver, stomach, breast, lung, and colorectal are the most common types of cancer.

Further key findings from the report suggest:
  • Molecular diagnostics segment is expected to witness the fastest growth over the forecast period, owing to the high usage of the technology for disease diagnosis
  • Infectious disease application segment dominated the market in 2019 due to rising prevalence of tuberculosis, hepatitis, and other infectious diseases
  • North America dominated the in vitro diagnostics market in 2019, owing to presence of key players and a rise in launch of new products in major countries like U.S. and Canada
  • Asia Pacific is expected to exhibit the fastest CAGR over the forecast period owing to number of products are being launched in hospitals to provide accurate diagnosis
  • Major IVD market players are Qiagen, Danaher, Becton, Dickinson and Company, Siemens Healthineers, F. Hoffmann-La Roche Ltd., Hologic, Inc. (Gen-Probe), bioMerieux SA, Abbott Laboratories, Cepheid, and Sysmex Corporation

Please note: This product will be delivered within 48 business hours after receipt of order.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Abbott Laboratories
  • bioMerieux
  • Cepheid
  • Danaher
  • F. Hoffmann-La Roche Ltd
  • Hologic, Inc. (Gen Probe)
  • MORE
Chapter 1 Methodology and Scope
1.1. Research Methodology
1.2. Market segmentation & scope
1.3. Market definition
1.4. Information procurement
1.4.1. Purchased database
1.4.2. Internal database
1.4.3. Secondary sources & third party perspectives
1.4.4. Primary research
1.5. Information analysis
1.5.1. Data analysis models
1.6. Market formulation & data visualization
1.7. Data validation & publishing

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Global IVD Market Variables, Trends & Scope
3.1. IVD Market Lineage outlook
3.1.1. Medical Technology market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Regulatory Framework
3.3.1. Reimbursement framework
3.3.2. Standards & Compliances
3.4. Market Dynamics
3.4.1. Market Driver Analysis
3.4.1.1. Increasing demand for point of care diagnostics
3.4.1.2. Growing geriatric population
3.4.1.3. Introduction of technologically advanced diagnostics
3.4.1.4. Increasing prevalence of chronic diseases
3.4.2. Market Restraint Analysis
3.4.2.1. High cost of devices
3.4.2.2 Stringent regulatory policies
3.5. Global IVD Market Analysis Tools
3.5.1. Industry Analysis - Porter’s
3.5.1.1. Supplier Power: (Moderate to high due to presence of many manufacturers)
3.5.1.2. Buyer Power: (Low due to presence of primary clinics and diagnostic labs entering into long-term contract)
3.5.1.3. Substitution Threat: (Moderate to Low due to high Accuracy of diagnostic results)
3.5.1.4. Threat from new entrant: (Moderate due to brand recognition of the existing players)
3.5.1.5. Competitive rivalry: (High due to increasing mergers & acquisitions by major players)
3.5.2. PESTEL Analysis
3.5.2.1. Political Landscape
3.5.2.2. Environmental Landscape
3.5.2.3. Social Landscape
3.5.2.4. Technology Landscape
3.5.2.5. Legal Landscape
3.5.3. Major Deals & Strategic Alliances Analysis
3.5.3.1. Joint Ventures
3.5.3.2. Mergers & Acquisitions
3.5.3.3. Licensing & Partnership
3.5.3.4. Technology Collaborations
3.5.3.5. Strategic Divestments

Chapter 4. Global IVD Market - Competitive Analysis
4.1. Recent developments & impact analysis, by key market participants
4.2. Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
4.3. Vendor Landscape
4.3.1. List of key distributors and channel partners
4.3.2. Key company market share analysis, 2019
4.4. Public Companies
4.4.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
4.4.2. Company Market Share
4.4.3. Competitive Dashboard Analysis
4.4.4. Market Differentiators
4.4.5. Synergy Analysis: Major Deals & Strategic Alliances
4.5. Private Companies
4.5.1. List of key emerging companies
4.5.2. Regional network map
4.5.3. Company market position analysis (geographic presence, product portfolio, key alliance, industry experience)

Chapter 5. Global IVD Market: Product Estimates & Trend Analysis
5.1. Definitions & Scope
5.2. Global IVD Market, by Product, 2016 - 2027
5.3. Market Size & Forecasts and Trend Analyses, 2016 - 2027 for the following,
5.3.1. Instruments
5.3.1.1 Instrument IVD Market, 2016 - 2027 (USD Million)
5.3.2. Reagents
5.3.1.1 Reagents IVD Market, 2016 - 2027 (USD Million)
5.3.3. Services
5.3.1.1 Services IVD Market, 2016 - 2027 (USD Million)

Chapter 6. Global IVD Market: Technology Estimates & Trend Analysis
6.1. Definitions & Scope
6.2. Technology market share analysis, 2019 & 2027
6.3. Global IVD Market, by Technology, 2016 to 2027
6.4. Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following,
6.4.1. Immunoassay
6.4.1.1 Immunoassay IVD Market, 2016 - 2027 (USD Million)
6.4.2. Hematology
6.4.2.1 Hematology IVD Market, 2016 - 2027 (USD Million)
6.4.3. Clinical Chemistry
6.4.3.1 Clinical Chemistry IVD Market, 2016 - 2027 (USD Million)
6.4.4. Molecular Diagnostics
6.4.4.1 Molecular Diagnostics IVD Market, 2016 - 2027 (USD Million)
6.4.5. Coagulation
6.4.5.1 Coagulation IVD Market, 2016 - 2027 (USD Million)
6.4.6. Microbiology
6.4.6.1 Microbiology IVD Market, 2016 - 2027 (USD Million)
6.4.7. Others
6.4.7.1 Others IVD Market, 2016 - 2027 (USD Million)
6.5. Technology Markets, by Product, 2016 to 2027:
6.5.1. Immunoassay
6.5.1.1 Instruments
6.5.1.1.1 Instrument IVD Market, 2016 - 2027 (USD Million)
6.5.2.1 Reagents
6.5.2.1.1 Reagents IVD Market, 2016 - 2027 (USD Million)
6.5.3.1 Services
6.5.3.1.1 Services IVD Market, 2016 - 2027 (USD Million)
6.5.2. Hematology
6.5.2.1 Instruments
6.5.2.1.1 Instrument IVD Market, 2016 - 2027 (USD Million)
6.5.2.2. Reagents
6.5.2.2.1 Reagents IVD Market, 2016 - 2027 (USD Million)
6.5.2.3 Services
6.5.2.3.1 Services IVD Market, 2016 - 2027 (USD Million)
6.5.3. Clinical Chemistry
6.5.3.1 Instruments
6.5.3.1.1 Instrument IVD Market, 2016 - 2027 (USD Million)
6.5.3.2. Reagents
6.5.3.2.1 Reagents IVD Market, 2016 - 2027 (USD Million)
6.5.3.3 Services
6.5.3.3.1 Services IVD Market, 2016 - 2027 (USD Million)
6.5.4. Molecular Diagnostics
6.5.4.1 Instruments
6.5.4.1.1 Instrument IVD Market, 2016 - 2027 (USD Million)
6.5.4.2. Reagents
6.5.4.2.1 Reagents IVD Market, 2016 - 2027 (USD Million)
6.5.4.3 Services
6.5.4.3.1 Services IVD Market, 2016 - 2027 (USD Million)
6.5.5. Coagulation
6.5.5.1 Instruments
6.5.5.1.1 Instrument IVD Market, 2016 - 2027 (USD Million)
6.5.5.2. Reagents
6.5.5.2.1 Reagents IVD Market, 2016 - 2027 (USD Million)
6.5.5.3 Services
6.5.5.3.1 Services IVD Market, 2016 - 2027 (USD Million)
6.5.6. Microbiology
6.5.6.1 Instruments
6.5.6.1.1 Instrument IVD Market, 2016 - 2027 (USD Million)
6.5.6.2. Reagents
6.5.6.2.1 Reagents IVD Market, 2016 - 2027 (USD Million)
6.5.6.3 Services
6.5.6.3.1 Services IVD Market, 2016 - 2027 (USD Million)
6.5.7. Others
6.5.7.1 Instruments
6.5.7.1.1 Instrument IVD Market, 2016 - 2027 (USD Million)
6.5.7.2. Reagents
6.5.7.2.1 Reagents IVD Market, 2016 - 2027 (USD Million)
6.5.7.3 Services
6.5.7.3.1 Services IVD Market, 2016 - 2027 (USD Million)

Chapter 7. Global IVD Market: Application Estimates & Trend Analysis
7.1. Definitions & Scope
7.2. Application market share analysis, 2019 & 2027
7.3. Global IVD Market, by Application, 2016 to 2027
7.4. Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following,
7.4.1. Infectious Disease
7.4.1.1 Infectious Disease IVD Market, 2016 - 2027 (USD Million)
7.4.2. Diabetes
7.4.2.1 Diabetes IVD Market, 2016 - 2027 (USD Million)
7.4.3. Oncology
7.4.3.1 Oncology IVD Market, 2016 - 2027 (USD Million)
7.4.4. Cardiology
7.4.4.1 Cardiology IVD Market, 2016 - 2027 (USD Million)
7.4.5. Nephrology
7.4.5.1 Nephrology IVD Market, 2016 - 2027 (USD Million)
7.4.6. Autoimmune Disease
7.4.6.1 Autoimmune Disease IVD Market, 2016 - 2027 (USD Million)
7.4.7. Drug Testing
7.4.7.1 Drug Testing IVD Market, 2016 - 2027 (USD Million)
7.4.8. Others
7.4.8.1 Others IVD Market, 2016 - 2027 (USD Million)

Chapter 8. Global IVD Market: End Use Estimates & Trend Analysis
8.1. Definitions & Scope
8.2. End Use market share analysis, 2019 & 2027
8.3. Global IVD Market, by End Use, 2016 to 2027
8.4. Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following,
8.4.1. Hospitals
8.4.1.1 Instrument IVD Market, 2016 - 2027 (USD Million)
8.4.2. Laboratories
8.4.2.1 Instrument IVD Market, 2016 - 2027 (USD Million)
8.4.3. Home Care
8.4.3.1 Instrument IVD Market, 2016 - 2027 (USD Million)
8.4.4. Others
8.4.4.1 Instrument IVD Market, 2016 - 2027 (USD Million)

Chapter 9 Global IVD Market: Regional Estimates & Trend Analysis, by Product, Technology, Application, & End-use
9.1 Global IVD Market: Regional Movement Analysis, 2019 & 2027
9.2 Global IVD Market: Leading Players, 2019:
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3 SWOT Analysis, by Factor (Political & Legal, Economic And Technological)
9.3.1. North America
9.3.2. Europe
9.3.3. Asia Pacific
9.3.4. Latin America
9.3.5. Middle East & Africa
9.4 North America
9.4.1 North America IVD market, 2016 - 2027 (USD Million)
9.4.2 U.S.
9.4.2.1 U.S. IVD Market, 2016 - 2027 (USD Million)
9.4.3 Canada
9.4.3.1 Canada IVD Market, 2016 - 2027 (USD Million)
9.5. Europe
9.5.1 Europe IVD market, 2016 - 2027 (USD Million)
9.5.3 U.K.
9.5.3.1 U.K. IVD market, 2016 - 2027 (USD Million)
9.5.2 Germany
9.5.2.1 Germany IVD market, 2016 - 2027 (USD Million)
9.5.3 Spain
9.5.3.1 Spain IVD market, 2016 - 2027 (USD Million)
9.5.3 France
9.5.3.1 France IVD market, 2016 - 2027 (USD Million)
9.5.3 Italy
9.5.3.1 Italy IVD market, 2016 - 2027 (USD Million)
9.5.3 Russia
9.5.3.1 Russia IVD market, 2016 - 2027 (USD Million)
9.6 Asia Pacific
9.6.1 Asia Pacific IVD market, 2016 - 2027 (USD Million)
9.6.2 Japan
9.6.2.1 Japan IVD market, 2016 - 2027 (USD Million)
9.6.3 India
9.6.3.1 India IVD market, 2016 - 2027 (USD Million)
9.6.4 South Korea
9.6.4.1 South Korea IVD market, 2016 - 2027 (USD Million)
9.6.5 Singapore
9.6.5.1 Singapore IVD market, 2016 - 2027 (USD Million)
9.6.6 Australia
9.6.6.1 Australia IVD market, 2016 - 2027 (USD Million)
9.7 Latin America
9.7.1 Latin America IVD market, 2016 - 2027 (USD Million)
9.7.2 Brazil
9.7.2.1 Brazil IVD market, 2016 - 2027 (USD Million)
9.7.3 Mexico
9.7.3.1 Mexico IVD market, 2016 - 2027 (USD Million)
9.7.4 Argentina
9.7.4.1 Argentina IVD market, 2016 - 2027 (USD Million)
9.8 MEA
9.8.1 MEA IVD market, 2016 - 2027 (USD Million)
9.8.2 South Africa
9.8.2.1 South Africa IVD market, 2016 - 2027 (USD Million)
9.8.3 United Arab Emirates
9.8.3.1 United Arab Emirates IVD market, 2016 - 2027 (USD Million)
9.8.4 Saudi Arabia
9.8.4.1 Saudi Arabia IVD market, 2016 - 2027 (USD Million)

Chapter 10 Competitive Landscape
10.1 Strategy Framework
10.2 Heat Map Analysis of Private Companies
10.2.1 Company size
10.2.2 Distribution network
10.2.3 Product portfolio
10.2.4 Segment coverage
10.2.5 Geographic presence
10.2.6 Collaborations
10.2.7 Conclusion
10.3 Becton, Dickinson and Company
10.3.1 Company overview
10.3.2 Financial performance
10.3.3 Product benchmarking
10.3.4 Strategic initiatives
10.4 bioMerieux
10.4.1 Company overview
10.4.2 Financial performance
10.4.3 Product benchmarking
10.4.4 Strategic initiatives
10.5 Abbott Laboratories
10.5.1 Company overview
10.5.2 Financial performance
10.5.3 Product benchmarking
10.5.4 Strategic initiatives
10.6 Sysmex Corporation
10.6.1 Company overview
10.6.2 Financial performance
10.6.3 Product benchmarking
10.6.4 Strategic initiatives
10.7 Ortho Clinical Diagnostics
10.7.1 Company overview
10.7.2 Financial performance
10.7.3 Product benchmarking
10.7.4 Strategic initiatives
10.8 Danaher
10.8.1 Company overview
10.8.2 Financial performance
10.8.3 Product benchmarking
10.8.4 Strategic initiatives
10.9 Hologic, Inc. (Gen Probe)
10.9.1 Company overview
10.9.2 Financial performance
10.9.3 Product benchmarking
10.9.4 Strategic initiatives
10.10 Cepheid
10.10.1 Company overview
10.10.2 Product benchmarking
10.10.3 Strategic initiatives
10.11 F. Hoffmann-La Roche Ltd
10.11.1 Company Overview
10.11.2 Financial performance
10.11.3 Product benchmarking
10.11.4 Strategic initiatives
10.12 Siemens Healthineers
10.12.1 Company overview
10.12.2 Financial performance
10.12.3 Product benchmarking
10.12.4 Strategic initiatives
10.13 Instrumentation Laboratory
10.13.1 Company overview
10.13.2 Financial overview
10.13.3 Product benchmarking
10.13.4 Strategic initiatives
10.14 Leica Biosystems Nussloch Gmbh
10.14.1 Company overview
10.14.2 Product benchmarking
10.14.3 Strategic initiatives
10.15 Bio-Rad Laboratories, Inc.
10.15.1 Company overview
10.15.2 Financial performance
10.15.3 Product benchmarking
10.15.4 Strategic initiatives
10.16 Quidel Corporation
10.16.1 Company overview
10.16.2 Financial performance
10.16.3 Products benchmarking
10.16.4 Strategic initiatives
10.17 Qiagen N.V.
10.17.1 Company overview
10.17.2 Financial performance
10.17.3 Product benchmarking
10.17.4 Strategic initiatives
10.18 OraSure Technologies, Inc.
10.18.1 Company overview
10.18.2 Financial performance
10.18.3 Products benchmarking
10.18.4 Strategic initiatives
10.19 Stago
10.19.1 Company overview
10.19.2 Product benchmarking
10.19.3 Strategic initiatives

*Full List of Tables and Figures Available on Enquiry.
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Becton, Dickinson and Company
  • bioMerieux
  • Abbott Laboratories
  • Sysmex Corporation
  • Ortho Clinical Diagnostics
  • Danaher
  • Hologic, Inc. (Gen Probe)
  • Cepheid
  • F. Hoffmann-La Roche Ltd
  • Siemens Healthineers
  • Instrumentation Laboratory
  • Leica Biosystems Nussloch Gmbh
  • Bio-Rad Laboratories, Inc.
  • Quidel Corporation
  • Qiagen N.V.
  • OraSure Technologies, Inc.
  • Stago
Note: Product cover images may vary from those shown
Adroll
adroll